English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Iron deficiency anemia is the most common cause of anemia in obstetrics.1 Efficacy of oral iron therapy is limited in many patients because of dose-dependent side effects, lack of compliance, and insufficient duodenal iron absorption. Rapid correction of anemia depends completely on blood transfusion, the hazards of which are well known. Newer parenteral preparations are being considered a safer therapy than blood transfusion. Administration of 100 to 200 mg intravenous iron sucrose doses three times a week is an approved regimen by the Food and Drug Association (FDA). Although other high-dose scheme regimens have been published frequently for chronic kidney disease (CKD) patients, very few such dosing regimens are investigated in the obstetric population.2-4 High-dose iron sucrose therapy is now a known practice among nephrologists worldwide to manage anemia in dialysis patients even on consecutive day administration regimens.5-7 However, studies are lacking in obstetrics. This encouraged us to explore this high-dose (500 mg) regimen in an effort not only to treat anemia effectively but also safely and rapidly comparable to that of blood transfusions, and to reduce the loss to follow-up seen with the low-dose (200 mg) regimen. Hence, we prospectively studied a high-dose (500 mg) intravenous iron sucrose regimen utilizing an accelerated dosing frequency in antenatal and postnatal patients with iron deficiency anemia and compared it with a regimen of low-dose (200 mg) iron therapy in a small cohort of patients. Additionally, we compared the efficacy, safety, and benefits of the high-dose regimen.8

High-dose Accelerated vs Low-dose Frequent Regime of Iron Sucrose Therapy in Antenatal and Postnatal Women with Iron Deficiency